David Schenkein, M.D.
Dr. David Schenkein is a general partner at GV, where he co-leads the life science investment team. Previously, David spent ten years as chief executive officer and a member of the board of directors at Agios Pharmaceuticals, where he remains chairman.
David has been a hematologist and medical oncologist for 30 years. He currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Prior to joining Agios, David was the senior vice president, clinical hematology/oncology at Genentech, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for their BioOncology portfolio. While at Genentech, he served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine.
Prior to joining Genentech, he served as the senior vice president of clinical research at Millennium Pharmaceuticals, overseeing the clinical development and worldwide approval of Velcade, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. He serves on the board of directors of Denali Therapeutics.
David holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.